NASDAQ · Key Statistics

Bambusa Therapeutics Inc. (BBTX) P/E Ratio, ROE & Key Statistics

$16.24 NASDAQ: BBTX Market Cap $808.25M

Data as of Nov 16, 2026 (intraday, delayed) · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Bambusa Therapeutics Inc. (BBTX), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.6.16

Per share and size

MetricValue
Market capitalisationShare price times shares outstanding.$808.25M

Bambusa Therapeutics Inc. (BBTX) statistics — frequently asked questions

How much debt does Bambusa Therapeutics Inc. carry?

Bambusa Therapeutics Inc. (BBTX) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.